TaiRx, Inc. (6580.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Taiwan · ISIN TW0006580004
TaiRx, Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 8.22 m TWD | 27.88 m TWD |
| Gross profit | 1.34 m TWD | 10.09 m TWD |
| Operating income | -145.96 m TWD | -237.36 m TWD |
| EBIT | -138.56 m TWD | -222.28 m TWD |
| Net income | -138.84 m TWD | -221.13 m TWD |
| Diluted EPS – continuing operations | -1.26 TWD | -1.97 TWD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About TaiRx, Inc.
TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company's products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic devices and anti-body drugs for the use in cancer therapy. TaiRx, Inc. was founded in 2011 and is based in Taipei, Taiwan.
More stocks
- Instil Bio, Inc. (TIL)
- FUEL TECH, INC. (FTEK)
- PDS Biotechnology Corp (PDSB)
- Brand X Co. Ltd. (337930.KQ)
- Kaonmedia Co Ltd (078890.KQ)
- Electra Battery Materials Corp (ELBM.V)
- Chen Nan Iron Wire Co.,Ltd (2071.TWO)
- Harvard Apparatus Regenerative Technology, Inc. (HRGN)
- SAIHEAT Ltd (SAIH)
- Qualisys Holding AB (publ) (QSYS.ST)
- Namib Minerals Ordinary Shares (NAMM)
- Poled (487580.KQ)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.